IMR Stock Overview A clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Price History & Performance
Summary of share price highs, lows and changes for AC Immune Historical stock prices Current Share Price US$2.65 52 Week High US$4.73 52 Week Low US$2.06 Beta 1.26 1 Month Change -15.61% 3 Month Change -18.21% 1 Year Change -39.70% 3 Year Change -39.50% 5 Year Change -64.67% Change since IPO -81.07%
Recent News & Updates
Ac Immune Reports Positive Interim Results from Phase 2 Trial of Aci-7104.056 Active Immunotherapy in Early Parkinson’S Disease Nov 14
Insufficient new directors Nov 01
No longer forecast to breakeven Aug 09
New minor risk - Profitability Aug 08 AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million. Aug 07
New major risk - Revenue and earnings growth Jul 10 See more updates
Ac Immune Reports Positive Interim Results from Phase 2 Trial of Aci-7104.056 Active Immunotherapy in Early Parkinson’S Disease Nov 14
Insufficient new directors Nov 01
No longer forecast to breakeven Aug 09
New minor risk - Profitability Aug 08 AC Immune SA has filed a Follow-on Equity Offering in the amount of $80 million. Aug 07
New major risk - Revenue and earnings growth Jul 10
AC Immune SA, Annual General Meeting, Jun 20, 2024 May 24
New minor risk - Profitability May 21
Forecast to breakeven in 2025 May 15
Forecast to breakeven in 2026 Apr 17
Full year 2023 earnings released: CHF0.64 loss per share (vs CHF0.85 loss in FY 2022) Mar 15
New minor risk - Shareholder dilution Dec 20
AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million. Dec 17 AC Immune SA has completed a Follow-on Equity Offering in the amount of $50.05 million. Dec 16
AC Immune SA Announces the Promotion of Christopher Roberts from Interim Chief Financial Officer to Chief Financial Officer, Effective January 1, 2024
New major risk - Revenue and earnings growth Nov 06
AC Immune SA Announces Executive Changes Jul 27
AC Immune SA Receives FDA Fast Track Designation for Anti-Amyloid-Beta Active Immunotherapy, ACI-24 060, to Treat Alzheimer's Disease Jun 28
New major risk - Share price stability Jun 28
AC Immune SA Announces Not Stand for Re-Election of Board of Directors Jun 24
AC Immune SA, Annual General Meeting, Jun 23, 2023 May 25
AC Immune’s ACI-24.060 Anti-Amyloid Beta Vaccine for Alzheimer’s Shows Positive Initial Interim Safety and Immunogenicity in Phase 1b/2 ABATE Trial Jan 27
AC Immune’s Alzheimer’s Disease Vaccine-Candidate ACI-35.030 Selected for Further Development Dec 01
AC Immune SA Opens New Centers in Phase 1b/2 Trial Evaluating ACI-24 Targeting Abeta in Alzheimer’s Disease and Down Syndrome Oct 05
AC Immune SA Presents Detailed Data from the Phase II Crenezumab Alzheimer’s Prevention Initiative Study in Autosomal Dominant Alzheimer’s Disease Presented At AAIC Aug 03
AC Immune SA Provides Update on Alzheimer's Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease Jun 17
AC Immune SA, Annual General Meeting, Jun 24, 2022 May 27 AC Immune SA's Anti-Abeta Vaccine Results from Phase 1b Study in Down Syndrome Published in JAMA Neurology May 10
AC Immune SA Announces Executive Changes
AC Immune ACI-35.030 Phase 1b/2a Trial Interim Data Confirm Consistent Safety and Potent Immunogenicity of pTau Alzheimer’s Vaccine in High-dose Cohort Feb 16
AC Immune ACI-24 Data in Brain Communications Show Abeta Vaccine-Candidate Induces Immunity Against pyroGlu-Abeta, Key Driver of Alzheimer’s Disease Feb 05
Third quarter 2021 earnings released: CHF0.22 loss per share (vs CHF0.26 loss in 3Q 2020) Nov 09
AC Immune SA Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease Sep 02
AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta Jun 03
Full year 2020 earnings released: CHF0.86 loss per share (vs CHF0.64 profit in FY 2019) Mar 25
AC Immune SA Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine Mar 17
AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases Mar 11
AC Immune to Present New Data from Alpha-Synuclein and TDP-43 Programs at the AD/PD™ 2021 Virtual Conference Feb 25
AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study Feb 13
AC Immune SA Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease Feb 09
New 90-day high: €5.57 Feb 04
Ac Immune Reports Progress for Therapeutic Programs Targeting the Nlrp3 Inflammasome Pathway Jan 31
New 90-day high: €5.17 Jan 11
AC Immune SA Receives Competitive Target ALS Foundation Grant to Accelerate the Development of Proprietary Phosphorylated TDP-43 Immuno-assay Dec 17
AC Immune Sa Appoints Carl H. June as Board of Directors Nov 21
AC Immune SA Hires Johannes R. Streffer as Chief Medical Officer Nov 19
Revenue beats expectations Nov 14
Third quarter 2020 earnings released: CHF0.26 loss per share Nov 14
AC Immune and WuXi Biologics Strengthen Strategic Partnership to Accelerate AC Immune’s Anti-TDP-43 Antibodies into Clinical Development Nov 10
New 90-day low: €3.83 Oct 21
AC Immune SA Announces EU Grant Supports Collaboration to Accelerate Development of AC Immune's First-in-Class TDP-43 Diagnostic Agent Oct 11
AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer’s Disease Sep 24
New 90-day low: €4.25 Sep 24
First half earnings released Aug 06
New 90-day high - €7.95 Jul 16 Shareholder Returns IMR DE Biotechs DE Market 7D 1.3% 1.2% -0.3% 1Y -39.7% -14.3% 7.0%
See full shareholder returns
Return vs Market: IMR underperformed the German Market which returned 6.8% over the past year.
Price Volatility Is IMR's price volatile compared to industry and market? IMR volatility IMR Average Weekly Movement 7.6% Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: IMR's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: IMR's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company’s SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer’s disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD.
Show more AC Immune SA Fundamentals Summary How do AC Immune's earnings and revenue compare to its market cap? IMR fundamental statistics Market cap €254.77m Earnings (TTM ) -€42.53m Revenue (TTM ) €43.71m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) IMR income statement (TTM ) Revenue CHF 40.97m Cost of Revenue CHF 61.43m Gross Profit -CHF 20.46m Other Expenses CHF 19.41m Earnings -CHF 39.86m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.40 Gross Margin -49.93% Net Profit Margin -97.29% Debt/Equity Ratio 0%
How did IMR perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/26 18:18 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources AC Immune SA is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Thomas Shrader BTIG Alethia Young Credit Suisse Andrew Fein H.C. Wainwright & Co.
Show 4 more analysts 
